![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Multiple Sclerosis |
Free Subscription
2 Brain |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Multiple Sclerosis is free of charge.
Not all roads lead to the immune system: the genetic basis of multiple sclerosis
severity.
Brain. 2022 Nov 30:awac449. doi: 10.1093.
PubMed
Abstract available
Location, location, location: myelin repair and proximity to ventricular CSF in
multiple sclerosis.
Brain. 2022 Nov 30:awac448. doi: 10.1093.
PubMed
B Cells Drive MHC Class I-Restricted CD4 T Cells to Induce Spontaneous Central
Nervous System Autoimmunity.
J Immunol. 2022;209:1880-1891.
PubMed
Abstract available
Conceptualization, use, and outcomes associated with compassion in the care of
people with multiple sclerosis: a scoping review.
J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
PubMed
Abstract available
Structural and functional magnetic resonance imaging correlates of fatigue and
dual-task performance in progressive multiple sclerosis.
J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
PubMed
Abstract available
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple
sclerosis: A systematic review and meta-analysis.
Mult Scler. 2022 Dec 1:13524585221134213. doi: 10.1177/13524585221134213.
PubMed
Abstract available
Immune checkpoint inhibitors: A potential bright spot in the treatment of
progressive multifocal leukoencephalopathy in multiple sclerosis.
Mult Scler. 2022 Nov 30:13524585221137275. doi: 10.1177/13524585221137275.
PubMed
Management approach including pembrolizumab for fingolimod-associated progressive
multifocal leukoencephalopathy in a patient with relapsing-remitting multiple
sclerosis.
Mult Scler. 2022 Nov 30:13524585221137279. doi: 10.1177/13524585221137279.
PubMed
Abstract available
External validation of a clinical prediction model in multiple sclerosis.
Mult Scler. 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036.
PubMed
Abstract available
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple
sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Mult Scler. 2022 Nov 30:13524585221138507. doi: 10.1177/13524585221138507.
PubMed
Serum NfL but not GFAP predicts cognitive decline in active progressive multiple
sclerosis patients.
Mult Scler. 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.
PubMed
Abstract available
T cell responses to COVID-19 infection and vaccination in patients with multiple
sclerosis receiving disease-modifying therapy.
Mult Scler. 2022 Nov 28:13524585221134216. doi: 10.1177/13524585221134216.
PubMed
Abstract available
Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based
Cohort Study From 2001 to 2020 in British Columbia, Canada.
Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
PubMed
Abstract available
Treadmill aerobic training improve beam-walking test, up-regulate expression of
main proteins of myelin and myelination in the hippocampus of cuprizone-fed mice.
Neurosci Lett. 2023;792:136936.
PubMed
Abstract available
Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite
responsible for decreasing relapse frequency in the treatment of multiple
sclerosis.
PLoS One. 2022;17:e0278111.
PubMed
Abstract available
High prevalence of low-allele-fraction somatic mutations in STAT3 in peripheral
blood CD8+ cells in multiple sclerosis patients and controls.
PLoS One. 2022;17:e0278245.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by